Literature DB >> 31520484

Results of the ADHERE upper airway stimulation registry and predictors of therapy efficacy.

Erica Thaler1, Richard Schwab2, Joachim Maurer3, Ryan Soose4, Christopher Larsen5, Suzanne Stevens5, Damien Stevens5, Maurits Boon6, Colin Huntley6, Karl Doghramji6, Tina Waters7, Alan Kominsky8, Armin Steffen9, Eric Kezirian10, Benedikt Hofauer11, Ulrich Sommer12, Kirk Withrow13, Kingman Strohl14, Clemens Heiser11.   

Abstract

OBJECTIVE/HYPOTHESIS: The ADHERE Registry is a multicenter prospective observational study following outcomes of upper airway stimulation (UAS) therapy in patients who have failed continuous positive airway pressure therapy for obstructive sleep apnea (OSA). The aim of this registry and purpose of this article were to examine the outcomes of patients receiving UAS for treatment of OSA. STUDY
DESIGN: Cohort Study.
METHODS: Demographic and sleep study data collection occurred at baseline, implantation visit, post-titration (6 months), and final visit (12 months). Patient and physician reported outcomes were also collected. Post hoc univariate and multivariate analysis was used to identify predictors of therapy response, defined as ≥50% decrease in Apnea-Hypopnea Index (AHI) and AHI ≤20 at the 12-month visit.
RESULTS: The registry has enrolled 1,017 patients from October 2016 through February 2019. Thus far, 640 patients have completed their 6-month follow-up and 382 have completed the 12-month follow-up. After 12 months, median AHI was reduced from 32.8 (interquartile range [IQR], 23.6-45.0) to 9.5 (IQR, 4.0-18.5); mean, 35.8 ± 15.4 to 14.2 ± 15.0, P < .0001. Epworth Sleepiness Scale was similarly improved from 11.0 (IQR, 7-16) to 7.0 (IQR, 4-11); mean, 11.4 ± 5.6 to 7.2 ± 4.8, P < .0001. Therapy usage was 5.6 ± 2.1 hours per night after 12 months. In a multivariate model, only female sex and lower baseline body mass index remained as significant predictors of therapy response.
CONCLUSIONS: Across a multi-institutional study, UAS therapy continues to show significant improvement in subjective and objective OSA outcomes. This analysis shows that the therapy effect is durable and adherence is high. LEVEL OF EVIDENCE: 2 Laryngoscope, 130:1333-1338, 2020.
© 2019 The Authors. The Laryngoscope published by Wiley Periodicals, Inc. on behalf of The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Obstructive sleep apnea; drug-induced sleep endoscopy; surgery; upper airway stimulation

Year:  2019        PMID: 31520484     DOI: 10.1002/lary.28286

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  20 in total

1.  Influence of apnea vs hypopnea predominance in predicting mean therapeutic positive airway pressures among patients with obstructive sleep apnea.

Authors:  Jason L Yu; Yifan Liu; Akshay Tangutur; Monique Arnold; Everett G Seay; Alan R Schwartz; Raj C Dedhia
Journal:  J Clin Sleep Med       Date:  2021-11-01       Impact factor: 4.062

2.  Early objective adherence to hypoglossal nerve stimulation therapy.

Authors:  Phillip Huyett
Journal:  J Clin Sleep Med       Date:  2022-02-01       Impact factor: 4.062

3.  Hypoglossal Nerve Stimulation Therapy.

Authors:  Philipp Arens; Toni Hänsel; Yan Wang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

4.  Does race-ethnicity affect upper airway stimulation adherence and treatment outcome of obstructive sleep apnea?

Authors:  Meena Khan; Andre Stone; Ryan J Soose; Samuel M Cohen; Javier Howard; Robson Capasso; Deeyar Itayem; M Boyd Gillespie; Reena Mehra; Eugene Chio; Patrick J Strollo; Anna Menzl; Adam Kaplan; Quan Ni
Journal:  J Clin Sleep Med       Date:  2022-09-01       Impact factor: 4.324

5.  Home sleep apnea testing with peripheral arterial tonometry to assess outcome in upper airway stimulation.

Authors:  Dominik Hinder; Simon C Schams; Christoph Knaus; Kurt Tschopp
Journal:  J Clin Sleep Med       Date:  2022-09-01       Impact factor: 4.324

6.  A prognostic star was born: drug-induced sleep endoscopy for hypoglossal nerve stimulation.

Authors:  Raj C Dedhia; Phillip Huyett
Journal:  J Clin Sleep Med       Date:  2020-12-17       Impact factor: 4.062

7.  Hypoglossal nerve stimulation impact on a patient with obstructive sleep apnea and heart failure.

Authors:  Sophia Rokkas; Colin Huntley; Maurits Boon
Journal:  J Clin Sleep Med       Date:  2021-05-01       Impact factor: 4.062

8.  Relation between arousability and outcome of upper airway stimulation in the Stimulation for Apnea Reduction (STAR) Trial.

Authors:  Jason L Yu; Magdy Younes
Journal:  J Clin Sleep Med       Date:  2021-04-01       Impact factor: 4.062

9.  Improving outcomes of hypoglossal nerve stimulation therapy: current practice, future directions, and research gaps. Proceedings of the 2019 International Sleep Surgery Society Research Forum.

Authors:  Maria V Suurna; Ofer Jacobowitz; Jolie Chang; Ioannis Koutsourelakis; David Smith; Uri Alkan; Mark D'Agostino; Maurits Boon; Clemens Heiser; Paul Hoff; Colin Huntley; David Kent; Alan Kominsky; Richard Lewis; Joachim T Maurer; Madeline J Ravesloot; Ryan Soose; Armin Steffen; Edward M Weaver; Amy M Williams; Tucker Woodson; Kathleen Yaremchuk; Stacey L Ishman
Journal:  J Clin Sleep Med       Date:  2021-12-01       Impact factor: 4.062

10.  Referral of adults with obstructive sleep apnea for surgical consultation: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.

Authors:  David Kent; Jeffrey Stanley; R Nisha Aurora; Corinna G Levine; Daniel J Gottlieb; Matthew D Spann; Carlos A Torre; Katherine Green; Christopher G Harrod
Journal:  J Clin Sleep Med       Date:  2021-12-01       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.